Skip to search formSkip to main contentSkip to account menu

p17 gag peptide, human immunodeficiency virus

Known as: SLYNTVATL, serine-leucyl-tyrosyl-asparagyl-threonyl-valyl-alanyl-threonyl-leucine, HIV Gag p17 (77-85) 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Objective:T-cell receptor (TCR) gene therapy is an approach being considered for HIV-1, but epitope mutation is a significant… 
Highly Cited
2004
Highly Cited
2004
All thymically selected T cells are inherently cross-reactive, yet many data indicate a fine specificity in antigen recognition… 
2004
2004
The CTL response to the HLA-A*0201-restricted, HIV-1 p17 Gag77–85 epitope (SLYNTVATL; SL9) has been extensively studied in… 
Highly Cited
2002
Highly Cited
2002
ABSTRACT Following the introduction of highly active antiretroviral therapy (HAART), the incidence of Kaposi's sarcoma (KS) has… 
Highly Cited
2002
Highly Cited
2002
ABSTRACT HIV-specific CD8+ T cells are critical in controlling human immunodeficiency virus (HIV) replication. We present the… 
2001
2001
HLA-A*02 tetramers complexed to human immunodeficiency virus (HIV) Gag SLYNTVATL and HIV Pol ILKEPVHGV peptides were used to… 
1999
1999
To address the issue of clonal exhaustion in humans, we monitored HLA class I-restricted, epitope-specific CTL responses in an in… 
Highly Cited
1995
Highly Cited
1995
Initial studies suggested that major histocompatibility complex class I-restricted viral epitopes could be predicted by the… 
Highly Cited
1994
Highly Cited
1994
We have established long-term cultures of several cell lines stably and uniformly expressing human immunodeficiency virus type 1…